Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes [Yahoo! Finance]
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: Yahoo! Finance
Members: Prof. Dr. Colin Dayan, Prof. Dr. Desmond Schatz, Prof. Dr. Didac Mauricio, Dr. Luiza Caramori, Dr. Kei Kishimoto, Prof. Dr. Roberto Mallone, Dr. Sylvaine You. Leiden, The Netherlands, xx June 2024 – Amarna Therapeutics , (“Amarna” or “the Company”) a privately-held biotechnology company focused on developing transformative gene therapies for a range of rare and prevalent genetic diseases, including Type 1 Diabetes Mellitus (T1DM), is pleased to announce the formation of its new Scientific Advisory Board (SAB). The newly established SAB consists of seven distinguished international scientific opinion leaders. These experts bring extensive experience and knowledge in the fields of pre-clinical and clinical development, gene therapy, immunology, endocrinology, and regulatory affairs. The SAB will leverage its extensive expertise to ensure that Amarna's groundbreaking Nimvec™ AM510 program meets the highest scientific and regulatory standards. This initiative underscores t
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.MarketBeat
- Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile DermatomyositisGlobeNewswire
- Cartesian Therapeutics Announces New Employment Inducement Grant [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics Announces New Employment Inducement GrantGlobeNewswire
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.MarketBeat
RNAC
Earnings
- 5/8/24 - Miss
RNAC
Sec Filings
- 9/27/24 - Form SC
- 9/27/24 - Form 4
- 9/26/24 - Form 8-K
- RNAC's page on the SEC website